Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Feb 15, 2022 9:34am
167 Views
Post# 34429467

RE:RE:RE:PR - taking contract sales force inhouse

RE:RE:RE:PR - taking contract sales force inhousePaul is convinced that sales can grow substantially and thinks that physicians are not understanding the full benefits of prescriing Egrifta and Trogarzo.....Not sure that digital would be enough....How high could Egrifta sales be if Lipo patients were presribed Tesamorelin for prevention of Nash ,,,Hard to convince with digital 

scarlet1967 wrote:

There are still focusing on “face to face” sales when the direction of most industries including commercializing pharmaceutical companies is going digital!!

 

“The first add-on, MyTherapy MS, debuted last week with 1,000 multiple sclerosis patients already using it through a trial in Germany. Smartpatient plans to expand the MS module to Europe and the US later while also lining up more disease-specific modules for asthma, psoriasis, rheumatoid arthritis and HIV for debut over the next few months.

Pharma is fantastic when it comes to drug developments, but they’re just not close enough to patients, they don’t have direct access to them,” he said, adding that learning came after working together and relying on pharma companies to handle distribution.

 

Pharma companies have spent years launching medication adherence and just information or even game-type apps, but with little long-term success. Patients hesitate for several reasons: the potential for overload — one app per medication could be a lot to manage — and a lingering lack of trust in pharma.

 

Still, people do want health apps. Thirty-eight percent of patients surveyed recently by the Organisation for the Review of Care and Health Apps (ORCHA) said they use health apps, and 87% agreed they were satisfied with the experience. Almost half (49%) said doctors should be able to prescribe health apps just like they do with traditional medicines.”

 

Mobile app developer adds disease-specific modules for patients – and pharma partners – Endpoints News

 



<< Previous
Bullboard Posts
Next >>